Ronomilast

Drug Profile

Ronomilast

Alternative Names: AWD 12353; ELB 353

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ASTA Medica
  • Developer Acorda Therapeutics
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Germany (PO)
  • 08 Aug 2011 Phase-I development for Chronic obstructive pulmonary disease has been completed
  • 26 Apr 2010 Top-line adverse events and pharmacodynamics data from a phase I trial in volunteers released by Biotie Therapies Corp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top